![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Vernalis | LSE:VER | London | Ordinary Share | GB00B3Y5L754 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 6.17 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
30/9/2007 22:47 | Mike, thanks. Good to see my prediction of failure for VER's application appearing to come true. VOW, I did warn you. At least you said you didn't mind losing your money if it all went wrong; and I know you always invest on margin, so I guess you will lose considerably more than you invested. I doubt if VER shares are now even worth 15p. :-) | qazwsx123 | |
30/9/2007 15:11 | Thanks for that. I am surprised by that as it seemed fairly certain but have moved my stop today to respond to any mark down tomorrow. | ![]() vow | |
28/9/2007 18:08 | VOW, I doubt it. | qazwsx123 | |
28/9/2007 13:11 | You could so easily be talking about AZM the way it is going. | ![]() vow | |
28/9/2007 12:57 | VOW, by next week VER may have fallen to 30p, and if the news is bad they won't be worth anything imo. | qazwsx123 | |
28/9/2007 09:04 | So it looks like we will here from the FDA next week then. | ![]() vow | |
27/9/2007 10:51 | The falling share price looks like some bad news may have leaked. | qazwsx123 | |
27/9/2007 09:46 | Lets hope the FDA don't pull a funny on Frova - should we hear Friday or wait until Monday? | ![]() fhmktg | |
26/9/2007 23:13 | mach6, you're welcome P.S. Do you get the impression that VOW and the_doctor are one in the same? | qazwsx123 | |
26/9/2007 19:59 | Thanks QAZ. | mach6 | |
26/9/2007 15:55 | mach6, I could not see any reason to buy at that price. If they fall into the 20's it would probably be because they are only worth in the 10's. | qazwsx123 | |
25/9/2007 20:36 | QAZ, these seem to be heading towards the high 20`s, would you be a buyer at this level? | mach6 | |
21/9/2007 14:47 | VOW, don't pretend you are not disappointed that IC only rate VERNALIS as "Fair value" today. | qazwsx123 | |
21/9/2007 14:42 | Thanks for the heads up on the IC article. According to them approval is "expected" on the 30th, which is more than I knew. This also triggers an instant £20m milestone payment, which will see the company through through 2008. Turnover is up 23% on last year, which in this climate is not bad going. I thought it to be 50/50 so my bet is looking better than before. PS Qaz is only here to try and taunt me so best ignore him. | ![]() vow | |
21/9/2007 13:34 | I doubt it. At best it will be lower by then and at worst could collapse on a refusal or more delays on 30th. Have they managed to address all the safety issues? | qazwsx123 | |
21/9/2007 12:06 | That should ensure a good jump if the news is OK on 30th | ![]() fhmktg | |
21/9/2007 11:18 | Vernalis shares only rated as "Fair value" in Investors Chronicle today ahead of the FDA decision, whereas IC tipped AZM as a "Buy" in July and at a higher price (97p) than today! AZM should receive a lot more cash upfront from their expected "transforming deals in 2007" than Vernalis will in the coming months and through 2008 imo! | qazwsx123 | |
20/9/2007 18:03 | Vernalis are going to be Pipped by Meldex (Bioprogress old name) DBP117 - Anti-Migraine As previously announced, BioProgress is developing a triptan drug within its Soluleaves™ and Wafertab™ technology platforms. New manufacturing techniques have been developed, taken from the development work carried out on its DBP121 smoking cessation program. The product is entering into commercial scale up during Q4 2007. It is anticipated that revenues will be generated from partnership deals early in 2008. From new market assessments and data, BioProgress has increased its revenue expectations to reach 3% of the global $3.1billion triptan market, increased from 1-1.5% | ![]() daveperry | |
18/9/2007 14:42 | Rutter British Bio (BB)was one of the three main companies which make up VER. VER bought up the parts of BB left after the discredited drug trial. The trial destroyed BB and lost the PI's a lot of money. I felt sorry for the guy who had to reveal the flawed science and the staff who lost their jobs. I met the CEO at Oxford and was concerned before the S... h.. the F.. . I was lucky because I sold my shares at a reasonable profit. I have always emphasised the importance of seeing the management face to face at AGM's,etc if possible. It is a very important element in my research and in deciding top ups or to pull out. Hope this helps. | ![]() mwryder | |
18/9/2007 13:44 | Anyone. Has this company anything to do with what was once British Biotech. and what happened to Brit.Bio. TIA | rutter | |
18/9/2007 13:44 | Anyone. Has this company anything to do with what was once British Biotech. and what happened to Brit.Bio. TIA | rutter |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions